Evidence map›Paper›PMID 39704811›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Influence of dosimetry accuracy on the correlation with treatment outcome in a preliminary PSMA radiopharmaceutical therapy study.

Jiaxi Hu, Robert Seifert, Sofia Karkampouna, Carlos Vinicius Gomes, Song Xue, Ali Afshar-Ormieh, Axel Rominger, Kuangyu Shi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Outcome-driven dosimetry optimization for [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Clinical value of per-treatment whole-body single-time-point automated dosimetry for [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Observational
  4. Review
  5. Substantial decrease in tumor dose over subsequent cyles of [European journal of nuclear medicine and molecular imaging · 2025
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiaxi HuDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20, 3010, Bern, Switzerland.
Robert SeifertDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20, 3010, Bern, Switzerland.
Sofia KarkampounaUrology Research Laboratory, Department for BioMedical Research, University of Bern, Bern, Switzerland.
Carlos Vinicius GomesDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20, 3010, Bern, Switzerland.
Song XueDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20, 3010, Bern, Switzerland.
Ali Afshar-OrmiehDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20, 3010, Bern, Switzerland.
Axel RomingerDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20, 3010, Bern, Switzerland.
Kuangyu ShiDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20, 3010, Bern, Switzerland. kuangyu.shi@dbmr.unibe.ch.ORCID 0000-0002-8714-3084

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDespite the potential of dosimetry in optimizing personalized radiopharmaceutical therapy (RPT), its limited clinical implementation impedes the development of simplified protocols for routine adoption. However, simplifications may introduce errors in dosimetry, prompting questions about their impact on clinical practice. MATERIALS AND

methodsIn this retrospective study, we analyzed data from 21 patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) who underwent multiple cycles of

resultsSTPD showed a non-significant difference in correlation with PSA decline rate, despite a mean percentage error (MPE) of up to 36.44% in tumor dosimetry compared to MTPD (MTPD: rho = -0.39, p < 0.001; STPD: rho = -0.46, p < 0.001; Z = 0.58, p = 0.56). Both STPD

conclusionThe preliminary findings from a small cohort indicate that the reduced accuracy of a clinically simplified protocol may not diminish the clinical therapy outcome predictive value of dosimetry. Future thorough systematic investigations may be needed to determine the clinically acceptable level of accuracy for dosimetry.

Indexed as

DipeptidesHeterocyclic Compounds, 1-RingProstatic Neoplasms, Castration-ResistantRadiopharmaceuticalsAgedAged, 80 and overHumansMaleMiddle AgedRadiometryRetrospective StudiesTreatment OutcomeDipeptidesHeterocyclic Compounds, 1-RingRadiopharmaceuticals177Lu-PSMA-617DosimetryProstate cancerRadionuclide therapyTheranostics

Identifiers

PMID39704811
PMCPMC11928392

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.